Experts study the effects of a drug that targets the Epstein-Barr Virus in people living with MS; results show early menopause is associated with a faster rate of cognitive decline; and a new study on vitamin D levels offers new insights.
These noteworthy MS news highlights and more are included in our May Bulletin below – a 30-day snapshot of global news & publications on MS research, treatment and care.
ECTRIMS Bulletins can be sent to you every month, delivered straight to your inbox, via our free subscription service. Simply select all “topics” that are of interest to you, and when one of those appears in our news & publication cycle you’ll be sure to hear from us.
Select MS News
Medical News Today | 22 April 2022
Researchers are investigating the effects of a drug that targets the Epstein-Barr virus in people with multiple sclerosis (MS) in an ongoing phase 1 clinical trial.
Multiple Sclerosis News Today | 23 May 2022
People with high levels of free vitamin D in circulation before the age of 20 have a lower risk of developing multiple sclerosis (MS) later in life, a new study suggests.
MS News Today | 5 May 2022
Researchers have identified four new brain proteins that are targeted by inflammatory T-cells in multiple sclerosis (MS), which could aid in the development of more specific and safer treatments for people with the condition.
Multiple Sclerosis News Today | 4 May 2022
Administering the maresin-1 molecule — a natural anti-inflammatory in the body — in a mouse model of multiple sclerosis (MS) led to lower levels of inflammation and improved neurological function, a recent study showed.
News Medical Life Sciences | 27 April 2022
The rate of multiple sclerosis (MS) cases varies greatly by race and ethnicity. A new study suggests that the prevalence of MS in Black and white people is similarly high, while much lower in Hispanic and Asian people. The research is published in the April 27, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Select MS Publications
NeuroSens | 19 May 2022
Recent imaging studies in multiple sclerosis have focused on the association between cognitive dysfunction and grey-matter tissue loss, most notably of the cerebral cortex and thalamus. Of emerging interest is cerebellar atrophy and its impact on cognition
Multiple Sclerosis Journal | 13 May 2022
Editorial: Two years have elapsed since the beginning of the coronavirus disease 2019 (COVID-19) pandemic. In this time, the international multiple sclerosis (MS) community has tried, through national and international registries, to address a number of important emerging issues.
Springer Link | 4 May 2022
Study investigates if CNS fibrin deposition can be determined using molecular MRI, and to assess its capacity as a non-invasive imaging biomarker that corresponds to inflammatory response and barrier impairment.
Neurology | 3 May 2022
Results show early transition to menopause is associated with an accelerated rate of cognitive decline. This association may be further exacerbated by insomnia. Our findings highlight a need for studies of sleep-based interventions to mitigate cognitive decline in women who experience early menopause.
- Exploring the Utility of MRI-based ‘SuStaIn’ Disease Subtyping for Precision Medicine in Relapsing and Secondary Progressive MS
Neurology | 3 May 2022
Study shows the SuStaIn lesion-led subtype is associated with higher baseline brain MRI disease severity. NTZ and DMF reduced inflammatory disease activity in all SuStaIn subtypes with no significant differences in treatment response. SuStaIn MS subtyping did not discriminate responder heterogeneity as assessed by new lesion formation in these NTZ and DMF trials.